Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Nozomu Kawata"'
Autor:
Osamu Yokoyama, Masashi Honda, Tomonori Yamanishi, Yuki Sekiguchi, Kenji Fujii, Takashi Nakayama, Takao Mogi, Takeya Kitta, Chikara Ohyama, Koichi Kambe, Yoshikatsu Tanahashi, Isoji Sasagawa, Mikinobu Ootani, Eiyu Nozawa, Toshihiko Saito, Fumio Manabe, Yasutomo Suzuki, Hikaru Tomoe, Satoru Takahashi, Nozomu Kawata, Hisashi Matsushima, Taketo Kawai, Manami Kinjo, Takashi Fukagai, Atsuko Takahashi, Fumio Nakajima, Haruaki Sasaki, Norihiko Okuno, Toshiyuki Itoi, Yoshiyuki Ishiura, Atsushi Mizokami, Yosuke Matsuta, Norifumi Sawada, Kosei Miwa, Atsushi Otsuka, Yasuhito Funahashi, Masaki Yoshida, Motoi Tobiume, Akihiro Kawauchi, Hiroshi Okuno, Terukazu Nakamura, Noriko Ninomiya, Chie Matsushita, Atsushi Takenaka, Takeshi Watanabe, Toyohiko Watanabe, Noritaka Ishito, Yasuyo Yamamoto, Hiroshi Ikeda, Narihito Seki, Shigehiro Kanegae, Kenichi Suyama, Kazuyuki Sagiyama, Noriaki Tokuda, Hideki Sakai, Hiroaki Nishimura, Motoshi Kawahara
Publikováno v:
International Journal of Urology
OBJECTIVE To evaluate the efficacy and safety of onabotulinumtoxinA (botulinum toxin type A) 100 U in patients with overactive bladder and urinary incontinence. METHODS This was a phase III, randomized, double-blind, placebo-controlled trial in Japan
Autor:
Junichi Mochida, Satoru Takahashi, Nozomu Kawata, Masahiro Ogawa, Tsuyoshi Yoshizawa, Kenya Yamaguchi, Hitomi Ryuzaki, Daisuke Obinata
Publikováno v:
Internal Medicine
We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naive cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH
Autor:
Kei Kawana, Kenichiro Kobayashi, Hikaru Sugano, Aki Maebayashi, Noriko Yamamoto, Takahiro Nakajima, Mizuho Nagata, Masaji Nagaishi, Nozomu Kawata
Publikováno v:
Journal of Nihon University Medical Association. 77:55-58
Autor:
Satoru Takahashi, Junichi Mochida, Nozomu Kawata, Yutaro Hori, Tsuyoshi Matsui, Shugo Suzuki, Kenya Yamaguchi, Tsuyoshi Yoshizawa, Fuminori Sakurai, Sho Hashimoto, Daisuke Obinata, Daigo Funakoshi
Publikováno v:
Journal of Urology. 201
Autor:
Ryo Hasegawa, Satoru Takahashi, Daisaku Hirano, K. Satoh, Yataroh Yamanaka, Shuji Sugimoto, Kenya Yamaguchi, Junichi Mochida, Nozomu Kawata, Hitoshi Hirakata
Publikováno v:
Scandinavian Journal of Urology. 48:436-444
The aim of this study was to prospectively verify the relationship between the clinical efficacies of secondary hormone therapy for castration-resistant prostate cancer (CRPC) following first line hormone therapy and neuroendocrine differentiation (N
Autor:
Nozomu Kawata, Masayoshi Soma, Daisuke Obinata, Hiroki Nagase, Kyoko Fujiwara, Kenya Yamaguchi, Aya Sato, Noboru Fukuda, Satoru Takahashi
Publikováno v:
International Journal of Oncology. 43:1441-1446
We investigated the clinical significance of the expression levels of matrix metalloproteinase 9 (MMP-9) in renal cell carcinoma (RCC). In addition, we validated the efficacy of pyrrole imidazole polyamide (PIP) targeting MMP-9 on inhibiting prolifer
Autor:
Satoru Takahashi, Nozomu Kawata
Publikováno v:
Journal of Nihon University Medical Association. 72:142-145
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2016 (2016)
Journal of Oncology, Vol 2016 (2016)
Objectives. To clarify what kind of pathological factor is necessary for the extension of tumor diameter in localized RCC, we studied localized RCC patients.Methods. We retrospectively reviewed medical records of 237 RCC patients in our institute who
Autor:
Nozomu Kawata, Satoru Takahashi, Hitoshi Hirakata, Takumi Igarashi, Katsuhiko Sato, Tsuyoshi Yoshizawa, Yoshiyuki Wada, Shinichiro Kokubun
Publikováno v:
Journal of Nihon University Medical Association. 71:322-328
Autor:
Yasuhiro Okada, Yusuke Nagane, Taketo Ichinose, Kenya Yamaguchi, Nozomu Kawata, Hitoshi Hirakata, Satoru Takahashi
Publikováno v:
Urology. 69:1049-1053
OBJECTIVE To examine the immunoreactivity of tumors for matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2), and membrane type MMP 1 (MT-MMP-1), to evaluate the optimum assessment of inci